Preoperative Naples prognostic score is a reliable prognostic indicator for newly diagnosed glioblastoma patients

Junhong Li, Wanchun Yang, Yunbo Yuan, Mingrong Zuo, Tengfei Li, Zhihao Wang and Yanhui Liu*

Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, China

Background: Glioblastoma (GBM) accounts for approximately 80% of malignant gliomas and is characterized by considerable cellularity and mitotic activity, vascular proliferation, and necrosis. Naples prognostic score (NPS), based on inflammatory markers and nutritional status, has a prognostic ability in various cancers. In the current study, we aim to explore the prognostic value of operative NPS in GBM patients and compare the prognostic ability between NPS and controlling nutritional status (CONUT).

Materials and methods: The retrospective analysis was carried out on consecutive newly diagnosed GBM patients who had undergone tumor resection at West China Hospital from February 2016 to March 2019. All statistical analyses were conducted using SPSS software and R software.

Results: A total of 276 newly diagnosed GBM patients were enrolled in the current study. Overall survival (OS) ($p < 0.001$) and tumor location ($p = 0.007$) were significantly related to NPS. Serum albumin concentrate, cholesterol concentrate, neutrophil-to-lymphocyte ratio, lymphocyte ratio, and CONUT score were all significantly associated with NPS ($p < 0.001$). The Kaplan–Meier curve indicated that NPS (log-rank test, $p < 0.001$) and CONUT score (log-rank test, $p = 0.023$) were significantly associated with OS. Multivariate Cox regression revealed that both NPS and CONUT score served as independent prognostic indicators. The prognostic model with NPS had the strongest prognostic capability and best model-fitting.

Conclusion: In the current study, NPS is found as an independent prognostic indicator for patients with newly diagnosed GBM, and the prognostic ability of NPS is superior to CONUT score.

KEYWORDS
naples prognostic score, glioblastoma, inflammation, nutrition, prognosis
Introduction

Gliomas are the most common primary malignant brain tumors in adults, which can occur anywhere in the central nervous system but primarily occur in the brain and originate in the glial tissue. Glioblastoma (GBM), the World Health Organization (WHO) grade 4 glioma, accounts for approximately 80% of malignant gliomas and is characterized by considerable cellularity and mitotic activity, vascular proliferation, and necrosis. The median overall survival (OS) is about 15 months in patients with this incurable disease, even after receiving standardized radiotherapy and temozolomide (TMZ), and there also remains a very high risk of recurrence. Despite considerable effort, little progress has been made toward prolonged survival in GBM.

In 1863, Rudolf Virchow firstly introduced the concept “inflammation and cancer” based on the observation on leukocytes in neoplastic tissues. In recent years, researchers have found that inflammation plays a crucial role in tumorigenesis, which is also considered as a hallmark feature of cancer development and progression. Systemic inflammatory response, mainly produced by peripheral immune cells, could indirectly reflect the severity of local malignancy. Peripheral blood neutrophil, lymphocyte, monocyte, and platelet are widely used as systemic inflammatory markers for predicting prognosis and evaluating therapeutic response of tumors. Nutrition is also proposed to play an essential role in cancer progression based on the principle that it can also cause oxidative stress, augment a cascade of molecular reactions in cells, and alter the metabolic state of tissues. Patients with wasting diseases like malignancies usually have weak physical conditions. Nutritional markers like albumin, hemoglobin, and BMI have been proven to be effective predictive indicators for disease progression and play a prognostic role.

Naples prognostic score (NPS), based on inflammatory markers and nutritional status, was firstly introduced in the research of colorectal cancer by Galizia et al. So far, the prognostic significance has been validated in various cancers. Controlling nutritional status (CONUT) score is also a useful nutritional marker to evaluate nutritional status and predict prognosis in cancer patients, which is similar in composition with NPS. Recent studies have reported that both preoperative and postoperative CONUT score serve as an independent prognostic indicator for GBM patients. In the current study, we aim to explore the prognostic value of preoperative NPS in GBM patients and compare the prognostic ability between NPS and CONUT.

Materials and methods

Patients

The retrospective analysis was carried out on consecutive newly diagnosed GBM patients who had undergone tumor resection at West China Hospital from February 2016 to March 2019. All the patients underwent a craniotomy on GBM with gross total resection (GTR) or subtotal resection (STR), and their baseline clinical data were retrieved from the hospital information system. The extent of resection was determined by surgical records and postoperative magnetic resonance imaging (MRI) and computed tomography (CT). The pathological diagnosis criteria followed the 2016 WHO classification of CNS tumors. These patients were followed up until March 2021.

The exclusion criteria were as follows: (1) younger than 18 years; (2) partial resection or biopsy; (3) absence of definite pathological diagnosis; (4) incomplete baseline clinical data; (5) receiving adjuvant therapy including radiotherapy, chemotherapy, and corticosteroid before surgery; (6) absence of preoperative MRI; (7) presence of history of infectious diseases, blood system diseases, or other malignancies before surgery; (8) recurrent GBM; and (9) lost to follow-up.

Parameter assessment

The following clinical variables were retrieved from the hospital information system: (1) demographics: age at diagnosis and gender; (2) preoperative conditions: Karnofsky performance status (KPS) score and presence of preoperative seizures; (3) imaging characteristics: tumor locations and maximum diameter. The maximum diameter was defined as the longest distance of the maximum section in gadolinium-enhanced T1 sequence. If there was no significant tumor enhancement, the T2 FLAIR sequence was applied; (4) pathological markers: Ki-67 index and the status of isocitrate dehydrogenase-1 (IDH-1); (5) conditions of adjuvant therapy; (6) blood test results: serum albumin, cholesterol, neutrophil count, lymphocyte count, and monocyte count. Routine blood test was conducted within 3 days before operation in our center.

NLR was defined as neutrophil count/lymphocyte count, and LMR was defined as lymphocyte count/monocyte count. NPS was calculated from serum albumin, cholesterol, and BMI. NPS and CONUT were calculated based on the count of serum albumin, cholesterol, and lymphocyte according to the previous study.

After initial treatment, the patients were followed up every 3–6 months. OS was defined as the duration from the date of operation to death or the end of the observation period.

Statistical analysis

All statistical analyses were conducted using SPSS software (Version 22.0, IBM Co., Armonk, NY, USA) and R software (Version 3.6.1). Continuous variables were presented as mean ± standard deviation (SD) or median with interquartile range (IQR), and categorical variables were presented as frequency and...
percentage. Categorical variables were compared using the chi-square test. Data that conformed to the normal distribution were compared using Student’s t-test; otherwise, Mann–Whitney U test or Kruskal–Wallis test was applied. Kaplan–Meier (K-M) curves were applied to calculate cumulative OS using the log-rank test. The Cox regression analyses were employed to determine the influences of risk factors for OS in GBM patients. Variables with p-value <0.1 in univariate analysis were included into backward stepwise multivariate Cox regression. Harrell’s concordance index (C-index) and Akaike information criterion (AIC) were calculated to evaluate prognostic models. Higher C-index indicated better predictive accuracy, while lower AICs indicated superior model-fitting (26, 27). A two-sided p-value <0.05 was referred to as statistically significant difference.

Ethics statement

This study was approved by the Ethical Committee of Sichuan University and conducted according to the principles expressed in the Declaration of Helsinki. All patients and their authorized trustees were informed before surgery and signed their informed consent to use their clinical data for research purposes.

Results

Baseline characteristics

After screening (Figure 1), a total of 276 newly diagnosed GBM patients were enrolled in the current study, including 185 (67.0%) men and 91 (33.0%) women (Table 1). The average age at diagnosis was 53.41 years. Forty-four (15.9%) patients had seizures before surgery, and 102 (37.0%) patients had a better KPS score (>80). Detailed tumor locations and maximum diameter are listed in Table 1. As for postoperative treatment, 217 patients received the Stupp’s regimen that contained 42-day concomitant radiochemotherapy and subsequent 6–12 consecutive cycles of TMZ alone, whereas the other 59 patients did not receive adjuvant therapy or discontinued the treatment at an early stage due to various reasons. High Ki-67 index was detected in 121 (43.8%) patients, and 35 (12.7%) patients had IDH-1 mutation. CONUT score was divided into four groups according to the score system. There were 63 (22.8%), 186 (67.4%), and 27 (9.8%) patients, respectively, in the Normal group, Light group, and Moderate group. No patient was included in the Severe group. Based on the definition of NPS, 41 (14.9%), 150 (54.3%), and 85 (30.8%) patients were classified into Group 0, Group 1, and Group 2, respectively.

Associations between NPS and clinical variables

Table 1 depicts the relationships between NPS and other clinical variables. OS (p < 0.001) and tumor location (p = 0.007) were significantly related to NPS, while other variables including age at diagnosis (p = 0.250), gender (p = 0.121), preoperative seizures (p = 0.268), KPS score (p = 0.653), hemisphere (p = 0.456), maximum diameter (p = 0.240), adjuvant therapy (p = 0.081), Ki-67 index (p = 0.327), and IDH-1 mutation status (p = 0.192) were not evidently connected with NPS. As for components of NPS, four
| Clinical Characteristic | Total (n = 276) | Naples Prognostic Score | p-value |
|-------------------------|-----------------|-------------------------|---------|
|                         | Group 0 (n = 41) | Group 1 (n = 150) | Group 2 (n = 85) |       |
| **Overall survival**    | 329 (193–550)   | 516 (282–885)         | 375 (198–547)   | 240 (128–428) | <0.001 |
| **Age at diagnosis**    | 53.41 ± 14.24   | 50.98 ± 11.27         | 53.13 ± 14.89   | 55.07 ± 14.30 | 0.250  |
| **Gender**              |                 |                        |                   |               |       |
| Male                    | 185 (67.0)      | 23 (56.1)              | 99 (66.0)        | 63 (74.1)     | 0.121  |
| Female                  | 91 (33.0)       | 18 (43.9)              | 51 (34.0)        | 22 (25.9)     |       |
| **Preoperative seizures** |               |                        |                   |               |       |
| Yes                     | 44 (15.9)       | 10 (24.4)              | 21 (14.0)        | 13 (15.3)     | 0.268  |
| No                      | 232 (84.1)      | 31 (75.6)              | 129 (86.0)       | 72 (84.7)     |       |
| **KPS**                 |                 |                        |                   |               |       |
| ≤80                     | 174 (63.0)      | 25 (61.0)              | 92 (61.3)        | 57 (67.1)     | 0.653  |
| >80                     | 102 (37.0)      | 16 (39.0)              | 58 (38.7)        | 28 (32.9)     |       |
| **Hemisphere**          |                 |                        |                   |               |       |
| Right                   | 130 (47.1)      | 21 (51.2)              | 65 (43.3)        | 44 (51.8)     | 0.456  |
| Left                    | 132 (47.8)      | 18 (43.9)              | 79 (52.7)        | 35 (41.2)     |       |
| Midline or bilateral    | 14 (5.1)        | 2 (4.9)                | 6 (4.0)          | 6 (7.1)       |       |
| **Location**            |                 |                        |                   |               |       |
| Frontal lobe            | 98 (35.5)       | 18 (43.9)              | 56 (37.3)        | 24 (28.2)     | 0.007  |
| Temporal lobe           | 54 (19.6)       | 6 (14.6)               | 18 (12.0)        | 30 (35.3)     |       |
| Parietal lobe           | 23 (8.3)        | 4 (9.8)                | 16 (10.7)        | 3 (3.5)       |       |
| Occipital lobe          | 7 (2.5)         | 2 (4.9)                | 3 (2.0)          | 2 (2.4)       |       |
| Insular lobe            | 10 (3.6)        | 1 (2.4)                | 7 (4.7)          | 2 (2.4)       |       |
| Other locations         | 84 (30.4)       | 10 (24.4)              | 50 (33.3)        | 24 (28.2)     |       |
| **Maximum diameter (mm)** |               |                        |                   |               |       |
| <50                     | 134 (48.6)      | 20 (48.8)              | 79 (52.7)        | 35 (41.2)     | 0.240  |
| ≥50                     | 142 (51.4)      | 21 (51.2)              | 71 (47.3)        | 50 (58.8)     |       |
| **Adjuvant therapy**    |                 |                        |                   |               |       |
| Yes                     | 217 (78.6)      | 35 (85.4)              | 122 (81.3)       | 60 (70.6)     | 0.081  |
| No or Undone            | 59 (21.4)       | 6 (14.6)               | 28 (18.7)        | 25 (29.4)     |       |
| **Ki-67**               |                 |                        |                   |               |       |
| <30%                    | 155 (56.2)      | 27 (65.9)              | 84 (56.0)        | 44 (51.8)     | 0.327  |
| ≥30%                    | 121 (43.8)      | 14 (34.1)              | 66 (44.0)        | 41 (48.2)     |       |
| **IDH-1**               |                 |                        |                   |               |       |
| Mutant                  | 35 (12.7)       | 8 (19.5)               | 20 (13.3)        | 7 (8.2)       | 0.192  |
| Wild type               | 241 (87.3)      | 33 (80.5)              | 130 (86.7)       | 78 (91.8)     |       |
| **Albumin (g/ml)**      | 4.28 (4.03–4.52) | 4.52 (4.27–4.67)      | 4.32 (4.15–4.50) | 3.96 (3.75–4.33) | <0.001 |
| **Cholesterol (mg/dl)** | 172.47 (149.36–195.96) | 199.92 (186.00–216.36) | 173.24 (150.23–198.38) | 156.23 (132.25–168.99) | <0.001 |
| **NLR**                 | 2.56 (1.84–4.21) | 1.62 (1.33–2.01)      | 2.35 (1.84–3.36) | 4.03 (3.27–6.29) | <0.001 |
| **LMR**                 | 4.03 (2.91–5.30) | 5.52 (4.89–6.94)      | 4.23 (3.13–5.53) | 2.88 (2.07–3.66) | <0.001 |
| **CONUT score**         |                 |                        |                   |               |       |
| Normal                  | 63 (22.8)       | 33 (80.5)              | 26 (17.3)        | 4 (4.7)       | <0.001 |
| Light                   | 186 (67.4)      | 8 (19.5)               | 118 (78.7)       | 60 (70.6)     |       |
| Moderate                | 27 (9.8)        | 0 (0.0)                | 6 (4.0)          | 21 (24.7)     |       |
| Severe                  | 0 (0.0)         | 0 (0.0)                | 0 (0.0)          | 0 (0.0)       |       |

Data are presented as n (%), mean ± SD, or median (25th, 75th quartile). Significant findings (p < 0.05) are expressed in bold and italic. KPS, Karnofsky performance status; IDH-1, Isocitrate dehydrogenase-1; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; CONUT, Controlling Nutritional Status.
Peripheral markers were all significantly associated with NPS ($p < 0.001$). There were significant differences between NPS groups 0, 1, and 2 in CONUT score ($p < 0.001$).

**Prognostic value of NPS**

As shown in Figure 2, the K-M curve was firstly employed to evaluate the prognostic significance of NPS and CONUT score in GBM patients. The results indicated that NPS (log-rank test, $p < 0.001$) and CONUT score (log-rank test, $p = 0.023$) were significantly associated with OS.

Cox regression analysis was used to further determine the prognostic roles of clinical variables (Table 2). In univariate Cox regression, elder patients, male, lower KPS score, longer maximum diameter, uncompleted adjuvant therapy, and IDH-1 wild type were significantly associated with poor prognosis. Tumor location was also evidently related to OS. Albumin $\geq 4$ g/dl and cholesterol $> 180$ mg/dl were in connection with favorable prognosis, while NLR $> 2.96$ indicated poor prognosis. CONUT score and NPS were also significantly related to prognosis, and hazard ratios were raised accompanied by the increase of the score. Multivariate Cox regression indicated that both CONUT score and NPS served as independent prognostic indicators. Other independent prognostic indicators included age, adjuvant therapy, and IDH-1 status.

**Prognostic model based on NPS and CONUT**

Prognostic models were conducted to further compare the prognostic ability between NPS and CONUT score (Table 3). The basic model constituted of independent variables from multivariate Cox regression except NPS and CONUT score. The results indicated that the prognostic ability of the basic model with either NPS (C-index, 0.645; AIC, 2,332.11) or CONUT (C-index, 0.624; AIC, 2,343.53) was superior to the basic model alone (C-index, 0.614; AIC, 2,347.70). Among these models, Model NPS had the largest C-index and the lowest AIC, which indicated the strongest prognostic capability and best model-fitting.

**Discussion**

In recent years, NPS has been widely researched in patients with malignancies, such as colorectal cancer, pancreatic cancer, endometrial cancer, lung cancer, gastric cancer, and esophageal squamous cell carcinoma (18–20, 28–30). These studies have found that preoperative NPS served as a reliable indicator to effectively predict prognosis mainly including OS and progression-free survival (PFS). In the current study, we attempt to explore the prognostic significance of preoperative NPS in newly diagnosed GBM patients. The results from our research are consistent with previous research, which indicates that NPS is an independent prognostic predictor.

Inflammation and malnutrition are basic characteristics for patients with malignancies. Tumor microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival, and migration. Many cancers arise from sites of infection, chronic irritation, and inflammation (8, 31). Changes in systemic inflammation could reflect the progression of local inflammation in tumors or adjacent to tumors; thus, researchers use peripheral blood immune cells to evaluate the progression of disease. In fact, these methods are also applied in patients with chronic medical disease such as coronary heart disease, systemic lupus erythematosus, and end-stage renal disease (32–34). The representative blood inflammatory markers mainly include leukocyte, neutrophil, lymphocyte, platelet, monocyte, and their combinations like neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio, which have been widely used in estimating conditions of diseases.

Nutrition status plays different roles in tumorigenesis and disease progression. On the one hand, nutrition and dietary factors have been associated with cancer risk. Nutrition/dietary components are likely to have an effect on an individual’s risk of cancer and that the mechanism by which cancer risk is affected is likely to be through epigenetic modification of an individual’s genome (35, 36). On the other hand, endless growth of malignancies has a tendency to deplete nutrients and leads to malnutrition conditions, and malnutrition can impact disease progression and survival in cancer patients (37). Various peripheral blood nutritional parameters have been reported to be associated with prognosis in patients with different malignancies. Among these markers, serum albumin concentrate and prognostic nutritional index (PNI) that contains albumin and lymphocyte have been used frequently (38–40). High concentration of nutritional markers, which indicates better nutritional status, usually relates to favorable prognosis. Cholesterol is an uncommon nutritional marker and is vital for the survival and growth of mammalian cells. It has been reported that cholesterol concentrate is significantly correlated with the incidence and progression of various malignancies like prostate cancer and breast cancer (41–44). As an indicator of nutrition, however, high cholesterol concentrate usually has been associated with favorable prognosis in cancer patients (45–47).

There has been a close relationship between systemic inflammatory response and nutrition (48). Nutritional status affects circulating immune cells, especially T cells, in population, metabolism, and function; hence abnormal nutritional conditions would break the balance of systemic inflammation.
FIGURE 2
Kaplan–Meier curves showing overall survival of GBM patients stratified by value of NPS (A) and CONUT score (B), respectively. GBM, glioblastoma; NPS, Naples prognostic score; CONUT, Controlling Nutritional Status; OS, overall survival.
The combination of systemic inflammatory markers and nutritional markers to predict prognosis and progression of disease has been widely used and proved to be useful, and the representatives include Glasgow prognostic score (GPS), CONUT, and NPS (16, 21, 50). Other different combinations of two kinds of markers are also determined to have effective prognostic ability in tumors (51, 52). Some of these prognostic scores like GPS and CONUT are also researched in patients with GBM, and the results are consistent with those of previous studies (25, 53).

### TABLE 2

Univariate and multivariate Cox regression for risk factors predictive of GBMs.

| Clinical Variables | Univariate Analysis | Multivariate Analysis |
|--------------------|---------------------|-----------------------|
|                    | HR                  | 95% CI                | p-value   | HR                  | 95% CI                | p-value   |
| Age at diagnosis   | <55 Reference       |                       |          | ≥55 1.929           | 1.491–2.496           | <0.001    |
| Gender             | Male Reference      |                       |          | Female 0.711        | 0.544–0.930           | 0.013     |
|                    | KPS ≤80 Reference   |                       |          | >80 0.743           | 0.573–0.963           | 0.025     |
| Hemisphere         | Right Reference     |                       |          |                       |                       |          |
|                    | Left 0.902          | 0.699–1.165           | 0.430    |                       |                       |          |
| Location           | Frontal lobe        | Reference             |          |                       |                       | 0.009     |
|                    | Temporal lobe       | 1.516                 | 1.072–2.144 | 0.019          | 1.107                 | 0.760–1.612 | 0.597    |
|                    | Parietal lobe       | 0.966                 | 0.599–1.558 | 0.887          | 1.319                 | 0.808–2.152 | 0.268    |
|                    | Occipital lobe      | 1.000                 | 0.436–2.294 | 0.999          | 1.691                 | 0.702–4.074 | 0.242    |
|                    | Insular lobe        | 1.094                 | 0.529–2.260 | 0.809          | 1.095                 | 0.518–2.317 | 0.812    |
|                    | Other regions       | 1.723                 | 1.264–2.349 | 0.001          | 1.418                 | 1.022–1.967 | 0.037    |
| Maximum diameter   | <50 Reference       |                       |          | ≥50 1.338           | 1.042–1.717           | 0.022     |
| Preoperative seizures | No Reference      |                       |          | Yes 0.953           | 0.681–1.334           | 0.778     |
| Adjuvant therapy   | Yes Reference       |                       |          | No or Undone 1.790  | 1.326–2.416           | <0.001    |
|                    | Wild type >30%      | 1.109                 | 0.864–1.424 | 0.416          | 1.272                 | 1.273–2.342 | <0.001   |
| IDH-1              | Mutant Reference    |                       |          | Mutant 2.153        | 1.421–3.262           | <0.001    |
|                    | Wild type <4        | 0.625                 | 0.484–0.805 | <0.001         | 0.731                 | 0.554–0.965 | 0.027    |
| Albumin (g/dl)     | ≥130 Reference      |                       |          | >180 0.561         | 0.431–0.731           | <0.001    |
|                    | ≤180 Reference      |                       |          | ≤2.96 1.610        | 1.193–2.172           | 0.002     |
|                    |                            |                       |          | ≤4.44 0.840        | 0.653–1.080           | 0.174     |
| CONUT score        | Normal Reference    |                       |          | Light 1.429         | 1.051–1.943           | 0.023     |
|                    |                             |                       |          | Moderate 1.795      | 1.116–2.888           | 0.013     |
|                    |                            |                       |          | Group 0 Reference  | <0.001                | Reference |
|                    |                            |                       |          | Group 1 1.584       | 1.090–2.302           | 0.016     |
|                    |                            |                       |          | Group 2 2.625       | 1.753–3.928           | <0.001    |

Significant findings (p < 0.05) are expressed in bold and italic.

KPS, Karnofsky performance status; IDH-1, Isocitrate dehydrogenase-1; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; CONUT, Controlling Nutritional Status; NPS, Naples prognostic score.
There are still some limitations in our research. First, it is a single-center retrospective clinical research, and multi-center collaborations and prospective experimental design are needed to verify the results. Second, it is hard for us to build a validation cohort due to the relatively small sample size. Third, patients lost to follow-up may cause selection bias in analysis. Fourth, some important glioma-related biomarkers like O6-methylguanine-DNA methyltransferase (MGMT) methylation and telomerase reverse transcriptase (TERT) mutation status were not included in the study due to incomplete pathological information.

**Conclusion**

To our knowledge, this is the first study to evaluate the prognostic role of preoperative NPS in newly diagnosed GBM patients. In the current study, we find NPS as an independent prognostic indicator for patients with newly diagnosed GBM patients, and the prognostic ability of NPS is superior to a similar prognostic score, CONUT. This easily acquired preoperative prognostic score has the potential to be used in clinical work, and will be verified in future research.

**Data availability statement**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**Ethics statement**

The studies involving human participants were reviewed and approved by Sichuan University. The patients/participants provided their written informed consent to participate in this study.

**Author contributions**

Conception and design: YL, JL, and WY. Provision of study materials or patients: JL, YY, and TL. Collection and assembly of data: MZ, ZW, and WY. Data analysis and interpretation: JL and YY. Manuscript writing: All authors. Final approval of manuscript: All authors.

**Funding**

This study was supported by the Key Research and Development Item from the Department of Science and Technology of Sichuan Province, China (No. 2017SZ0006).

**Acknowledgments**

We would like to express our gratitude to all the colleagues who have assisted clinical data collection. We would like to thank all the glioma patients who were...
admitted in our hospital who have contributed to the development of medicine.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**References**

1. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a ‘state of the science’ review. Neuro-Oncology (2014) 16(7):896–913. doi: 10.1093/neuonc/nou087

2. Omuoro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama (2013) 310(17):1842–50. doi: 10.1001/jama.2013.280319

3. Muir M, Gopakumar S, Traylor J, Lee S, Rao G. Glioblastoma multiforme: novel therapeutic targets. Expert Opin Ther Targets (2020) 24(7):605–14. doi: 10.1080/14728222.2020.1762646

4. Alexander BM, Cloughesy TF. A novel prognostic score in predicting cancer-specific survival in patients with resected esophageal squamous cell carcinoma. Front Oncol (2020) 10:595793. doi: 10.3389/fonc.2020.595793

5. Miyamoto Y, Hiyoshi Y, Daitoku N, Okadome K, Sakamoto Y, Yamashita K, et al. Naples Prognostic score is a useful prognostic marker in patients with metastatic colorectal cancer. Dis Colon Rectum (2019) 62(12):1485–93. doi: 10.1097/dclr.000000000000448

6. Nakagawa N, Yamada S, Sonohara F, Takami H, Hayashi M, Kanda M, et al. Clinical implications of Naples prognostic score in patients with resected pancreatic cancer. Ann Surg Oncol (2020) 27(3):887–95. doi: 10.1245/s10434-019-08047-7

7. Li Q, Cong R, Wang Y, Kong F, Ma J, Wu Q, et al. Naples Prognostic score is an independent prognostic factor in patients with operable endometrial cancer. Results from a retrospective cohort study. Gynecologic Oncol (2021) 160(1):91–8. doi: 10.1016/j.ygyno.2020.01.013

8. Ignacio de Ulbarri J, González-Madroño A, de Villar NG, González P, González-B, Mancha A, et al. CONUT: a tool for controlling nutritional status. first validation in a hospital population. Nutrition Hospitalk (2005) 20(1):38–45.

9. Kuroda D, Sawahama Y, Kurahige J, Iwashiki M, Eto T, Tokunaga R, et al. Controlling nutritional status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. Gastric Cancer (2018) 21(2):204–12. doi: 10.1007/s12028-017-0744-3

10. Arroyo E, Nowosrjati R, Thaiss CA, Hu B, Jin C, Flarell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 13(11):759–71. doi: 10.1038/nrc3611

11. Teo J, McNamara MG, Sargent DJ, Templeton AJ. Prognostic utility of platelet-lymphocyte ratio, neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in head and neck cancers: a meta-analysis. J Natl Cancer Institute (2014) 106(6):e124. doi: 10.1093/jnci/dju124

12. Ma JY, Liu Q. Clinicopathological and prognostic significance of lymphocyte to monocyte ratio in patients with gastric cancer: A meta-analysis. Int J Surg (London England) (2018) 56:67–71. doi: 10.1016/j.ijsu.2018.01.002

13. Kumarasamy C, Tiwary V. Prognostic utility of platelet-lymphocyte ratio, neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in head and neck cancers: A detailed PRISMA compliant systematic review and meta-analysis. J Natl Cancer Institute (2014) 106(6):e124. doi: 10.1093/jnci/dju124

14. Harrell FEJr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (2001) 19(4):2295–2312. doi: 10.1002/1097-0258(20010220)19:4<2295::aid-sim463>3.0.co;2-9

15. Bullock AF, Greenley SL, McKenzie GAG, Paton LW, Johnson MJ. Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis. Eur J Clin Nutr (2020) 74(11):1519–35. doi: 10.1038/s41420-020-0290-0

16. Castillo-Martinez L, Castro-Eguiluz D, Copca-Mendoza ET, Perez-Camargo DA, Reyes-Torres CA, Avila EA, et al. Nutritional assessment tools for the identification of malnutrition and nutritional risk associated with cancer treatment. Rev investigacion clinica; organo del Hosp Enfermedades de la Nutricion. (2018) 70(3):121–5. doi: 10.24875/ric.18002524

17. Galizia G, Lieto E, Auricchio A, Cardella F, Mabilia A, Podzemny V, et al. Naples Prognostic score, based on nutritional and inflammatory status, is an independent predictor of long-term outcome in patients undergoing surgery for colorectal cancer. Dis Colon Rectum. (2017) 60(12):1273–84. doi: 10.1097/dcr.0000000000000961

18. Xiong J, Wang Y, Kang W, Ma F, Liu H, Ma S, et al. Prognostic importance of the preoperative Naples prognostic score for patients with adenocarcinoma of the esophageagogastric junction. Front Oncol (2020) 10:595793. doi: 10.3389/ fonc.2020.595793

19. Li Q, Cong R, Wang Y, Kong F, Ma J, Wu Q, et al. Naples Prognostic score is an independent prognostic factor in patients with operable endometrial cancer. Results from a retrospective cohort study. Gynecologic Oncol (2021) 160(1):91–8. doi: 10.1016/j.ygyno.2020.01.013

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
33. Wang L, Wang C, Jia X, Yang M, Yu J. Relationship between neutrophil-to-lymphocyte ratio and systemic lupus erythematosus: A meta-analysis. (2020) 75. doi: 10.6061/cinetics/2020/e1450

34. Yuan Q, Wang J, Peng Z, Zhou Q, Xiao X, Xie Y, et al. Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese cohort study of chronic kidney disease (C-STREIDE). J Trans Med (2019) 17(1):86. doi: 10.1186/s12967-019-1808-4

35. Sapienza C, Issa JP. Diet, nutrition, and cancer epigenetics. Annu Rev Nutr (2016) 36:665–81. doi: 10.1146/annurev-nutr-121415-112634

36. Mayne ST, Playdon MC, Rock CL. Diet, nutrition, and cancer: past, present and future. Nat Rev Clin Oncol (2016) 13(8):504–15. doi: 10.1038/nrclinonc.2016.24

37. Mantzorou M, Koutelidakis A, Theocharis S, Giaginis C. Clinical value of nutritional status in cancer: What is its impact and how it affects disease progression and prognosis? Nutr Cancer (2017) 69(8):1151–76. doi: 10.1080/01635581.2017.1367947

38. Bao X, Liu F, Lin J, Chen Q, Chen L, Chen F, et al. Nutritional assessment and prognosis of oral cancer patients: a large-scale prospective study. BMC Cancer (2020) 20(1):146. doi: 10.1186/s12885-020-6604-2

39. Okadome K, Baba Y, Yagi T, Kiyozumi Y, Ishimoto T, Iwatsuki M, et al. Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer. Ann Surgery (2020) 274(1):693–700. doi: 10.1097/sla.0000000000002985

40. Zhang Y, Zhu JY, Zhou LN, Tang M, Chen MB, Tao M. Predicting the progression of gastric cancer by Albumin/Globulin ratio and the prognostic nutritional index. Nutr Cancer (2020) 72(4):635–44. doi: 10.1080/01635581.2019.1651347

41. Iannagrequalla J, Howard LE, Allott EH, Vidal AC, Castro-Santamaria R, et al. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Diseases (2018) 21(2):252–9. doi: 10.1038/s41391-017-0300-9

42. Murtola TJ, Kasurinen TVJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Diseases (2019) 22(1):66–76. doi: 10.1038/s41391-018-0087-0

43. Munir MT, Ponce C, Powell CA, Tarafdar K, Yanagita T, Choudhury M, et al. The contribution of cholesterol and epigenetic changes to the pathophysiology of breast cancer. J Steroid Biochem Mol Biol (2018) 183:1–9. doi: 10.1016/j.jsbmb.2018.05.001

44. Iso H, Ikeda A, Inoue M, Sato S, Trugane S. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer (2009) 125(11):2679–86. doi: 10.1002/ijc.24468

45. Zhou P, Li B, Liu B, Chen T, Xiao J. Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: A systematic review and meta-analysis. Clinica chimica acta; Int J Clin Chem (2018) 477:94–104. doi: 10.1016/j.cca.2017.11.039

46. Perrone F, Minari R, Bersanelli M, Bordi P, Tiseo M, Favari E, et al. The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors. Immunotherapy (Hagerstown Md 1997). (2020) 4(6):196–203. doi: 10.1007/cj.0000000000000321

47. Hao B, Peng X, Bi B, Yu M, Sang C, Chen Z. Preoperative serum high-density lipoprotein cholesterol as a predictor of poor survival in patients with clear cell renal cell cancer. Int J Biol Markers (2019) 34(2):168–75. doi: 10.1177/1724600819831404

48. Cordeiro LAE, Silva TH, de Oliveira LC, Neto JFN. Systemic inflammation and nutritional status in patients on palliative cancer care: A systematic review of observational studies. Am J Hospice Palliative Care (2020) 37(7):565–71. doi: 10.1177/1049909119886833

49. Alwarzrafiy Y, Kiernan K, MacIver NJ. Changes in nutritional status impact immune cell metabolism and function. Front Immunol (2018) 9:1055. doi: 10.3389/fimmu.2018.01055

50. McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev (2013) 39(5):534–40. doi: 10.1016/j.ctrv.2012.08.003

51. Chen YR, Chen YL, Ouyang SS, Xu HW, Li P, He LJ, et al. Prognostic efficacy of preoperative mGPS, SIS and LCS in patients with gastric cancer. Clinica chimica acta; Int J Clin Chem (2020) 511:81–9. doi: 10.1016/j.cca.2020.09.027

52. Fu X, Li T, Dui Y, Li J. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma. BMC Cancer (2019) 19(1):721. doi: 10.1186/s12885-019-5940-0

53. Topkan E, Selek U, Ozdemir Y, Yildirim BA, Guler OC, Ciner F, et al. Prognostic value of the Glasgow prognostic score for glioblastoma multiforme patients treated with radiotherapy and temozolomide. J Neuro-Oncology (2018) 139(2):411–9. doi: 10.1007/s11060-018-2879-4